Greenphire has expanded its agreement with Merck, known as MSD outside the US and Canada, to help minimise financial and travel barriers for clinical trial participants across the globe.
The expanded agreement between the companies now includes the use of Greenphire’s ClinCard, with rideshare integration for subjects across the clinical development network of Merck.
ClinCard does not impose costs on trial sites and helps to ensure participants are reimbursed quickly, enabling research sites to focus on key work related to carrying out clinical trials.
Greenphire CEO Jim Murphy said: “We are proud to expand this agreement with Merck to address participant obstacles across the company’s global clinical trial network.”
ClinCard streamlines the participant reimbursement and payment process through a simplified and automated workflow.
This eliminates the administrative burden on site staff and improves participant engagement and retention.
Additionally, ClinCard helps to keep trial participants on schedule and delivers payments immediately following a milestone or a visit.
Merck Research Laboratories Global Trial Optimisation head Kelly White said: “We are pleased to expand our agreement with Greenphire based upon our shared commitment to streamlining and improving the clinical trial experience for participants.
“Merck is dedicated to enrolling people in our clinical trials that appropriately reflect the patients we serve.”
Greenphire, which is engaged in automating global clinical trial financial processes, provides solutions that optimise study performances by streamlining payment and logistical workflows, from sponsors and clinical research organisations, to sites and patients.
Its EnvisiX, eClinicalGPS, ClinCard, and ConneX solutions can easily handle any type of trial design and complexity.